Date: 2015-07-30
Type of information: Licensing agreement
Compound: ARGX-110-based therapies
Company: Argen-X (Belgium - The Netherlands) University of Bern (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: monoclonal antibody. ARGX-110 is a first-in-class monoclonal antibody that potently blocks CD70-induced tumor cell proliferation and tumor escape from immune surveillance. CD70 is overexpressed in the majority of
cancer patients tested to date.
Disease: hematological cancers
Details: * On July 30, 2015, arGEN-X and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. The license agreement has arisen from a highly productive collaboration between the two groups, jointly announced in December 2014 at the annual ASH (American Society of Hematology) conference. Ongoing preclinical work has demonstrated the potential use of ARGX-110 to overcome imatinib resistance in chronic myelogenous leukemia (CML), data which are published in Science Translational Medicine.
“The multi-faceted clinical potential of ARGX-110 in CD70 positive tumors is unfolding rapidly as we progress through preclinical and clinical development. Together with our collaborators in Bern, our discovery that CD70 blockade overcomes resistance to tyrosine kinase inhibitor treatment in CML patients offers an exciting in-road into combination therapy with ARGX-110. Through this collaboration, we have built a deeper understanding of the role of leukemia stem cells (LSCs) in CML and how CD70 plays a role in establishment of resistance to standard of care therapies,” commented Hans de Haard, Chief Scientific Officer of arGEN-X.
Financial terms:
Latest news:
